Patients were classified as having progressive disease (PD) if they experienced a ≥ 20% increase in whole-body (WB) PSMA tumor volume (WB-PSMA-VOL) and had new lesions on interim PSMA-PET done after two cycles of 177Lu-PSMA RLT. Here, FOLH1 is linked to neoplasm.